Aki Prihti serves as a part-time CFO and is a board member of Medtentia.
He has almost 20 years’ experience of life science growth companies, both in operational and board roles.
Aki is one of the founders of Inveni Capital, a venture capital firm specialising in life sciences. He is also the CEO of Aplagon, a pharmaceutical company focused on developing proprietary, vascular injury targeting and locally acting, potent antithrombotic products known as APACs.
Aki also serves as a board member of Herantis Pharma Oyj and Aranda Pharma Oy.